OcaratuzumabOcaratuzumab
MedChemExpress (MCE)
HY-P99308
1169956-08-4
AME 133v
LY 2469298
Humanized Anti-MS4A1 Recombinant Antibody
95.00%
Please store the product under the recommended conditions in the Certificate of Analysis.
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC).
AME-133v (0.027-20 μg/mL) concentration-dependently inhibits the binding of biotinylated Rituximab to CD20 in SKW6.4 cells[1].
Kd: ~100 pM (CD20)[1] In Vitro AME-133v (0.027-20 μg/mL) concentration-dependently inhibits the binding of biotinylated Rituximab to CD20 in SKW6.4 cells[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Ocaratuzumab Related Antibodies
Humanized
Human IgG1 kappa
Human IgG1 kappa, Isotype Control
| | | |
| | | | | |
[1]. Forero-Torres A, et, al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1
18(5):1395-403. [Content Brief]
[2]. Cheney CM, et, al. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs. 2014 May-Jun
6(3):749-55. [Content Brief]